ArticleToxins2018
Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.
Article in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04996264 (Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes
Who cites it
40 citing papers in PubMed.
- Engineering Antivenom: Research Progress and Future Directions in Snakebite Envenoming Therapy.Annals of the New York Academy of Sciences · 2026Review
- Targeting Key Enzymatic Snake Venom Proteins Using Repurposed Small Molecule Inhibitors: Emerging Adjuncts to Antivenom Therapy.International journal of molecular sciences · 2026Review
- Article
- Article
- Breaking muscle: neurotoxic and myotoxic effects of Central American snake venoms and the relative efficacies of antivenom and varespladib.BMC biology · 2024Article
- Tissue damaging toxins in snake venoms: mechanisms of action, pathophysiology and treatment strategies.Communications biology · 2024Review
- Article
- Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms.Nature communications · 2023Article
- Considerations for the development of a field-based medical device for the administration of adjunctive therapies for snakebite envenoming.Toxicon: X · 2023Article
- Unraveling snake venom phospholipase APharmacological reports : PR · 2023Review
- Oral and IV Varespladib Rescue Experiments in Juvenile Pigs with Weakness Induced by Australian and PapuanToxins · 2023Article
- In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell's Viper (Toxins · 2023Article
- Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform.Frontiers in pharmacology · 2023Article
- Article
- Inhibitory Effects of Varespladib, CP471474, and Their Potential Synergistic Activity onMolecules (Basel, Switzerland) · 2022Article
- Review
- Article
- Bibliometric Analysis of Literature in Snake Venom-Related Research Worldwide (1933-2022).Animals : an open access journal from MDPI · 2022Article
- Article
- Ruthenium chloride inhibits the anticoagulant activity of the phospholipase AJournal of thrombosis and thrombolysis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an unmet need for economical snakebite therapies with long shelf lives that are effective even with delays in treatment. The orally bioavailable, heat-stable, secretory phospholipase A₂ (sPLA₂) inhibitor, LY333013, demonstrates antidotal characteristics for severe snakebite envenoming in both field and hospital use. A murine model of lethal envenoming by a Papuan taipan (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.